Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME - Disclosure of results of discontinued operations (Details)

v3.24.1
DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME - Disclosure of results of discontinued operations (Details) - CAD ($)
$ in Thousands
 12 Months Ended
Nov. 06, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of analysis of single amount of discontinued operations [line items]        
Revenues   $ 48,804 $ 54,335 $ 34,053 [1]
Cost of revenues   37,974 43,044 25,458 [1]
Gross profit before fair value adjustments   10,830 11,291 8,595 [1]
Fair value adjustments:        
Unrealized change in fair value of biological assets   0 (315) 6,308 [1]
Realized fair value adjustments on inventory sold in the year   (984) (1,814) (8,570) [1]
Total fair value adjustments   (984) (2,129) (2,262) [1]
Gross profit   9,846 9,162 6,333 [1]
General and administrative expenses   11,008 21,460 17,221 [1]
Selling and marketing expenses   10,788 11,473 6,725 [1]
Restructuring expenses   617 4,383 0 [1]
Share-based compensation   225 2,637 5,422 [1]
Total operating expenses   22,638 39,953 29,368 [1]
Operating loss   (12,792) (30,791) (23,035) [1]
Finance expenses, net   3,335 4,731 22,871 [1]
Loss before income taxes   (9,457) (26,060) (164) [1]
Income tax expense (benefit)   771 (1,138) 500 [1]
Net loss from discontinued operations, net of tax   0 (166,379) (17,854) [1]
Discontinued operations [member]        
Disclosure of analysis of single amount of discontinued operations [line items]        
Revenues $ 28,171     20,247
Cost of revenues 24,227     16,960
Gross profit before fair value adjustments 3,944     3,287
Fair value adjustments:        
Unrealized change in fair value of biological assets 399     902
Realized fair value adjustments on inventory sold in the year (2,528) $ (2,528) (226)
Total fair value adjustments (2,129)     676
Gross profit 1,815     3,963
General and administrative expenses 38,464     14,998
Impairment of goodwill, intangible assets, right-of-use assets and fixed assets 115,112     0
Selling and marketing expenses 4,912     2,270
Restructuring expenses 4,506     0
Share-based compensation 1,130     2,049
Total operating expenses 164,124     19,317
Operating loss (162,309)     (15,354)
Finance expenses, net (5,264)     (2,495)
Loss before income taxes (167,573)     (17,849)
Income tax expense (benefit) (1,194)     5
Net loss from discontinued operations, net of tax $ (166,379)     $ (17,854)
[1] Reclassified in respect of discontinued operations - see Note 25.